The 340B Plan mega-guidance just released by medical Resources and Services Administration clarifies how patients can receive deeply discounted drugs. Amid claims of fragile federal oversight and unclear vocabulary about eligibility, the 340B Drug Pricing Program has undergone many adjustments within the last few years Get more information . One major change to 340B outlined in HRSA’s newly proposed guidance is that patients must meet 6 specific conditions in order to be eligible for drug special discounts, which doubles the original 3. Under this long-awaited mega-guidance, an individual will be considered a patient of a protected entity, and therefore qualified to receive drug discounts, if all the following circumstances are met: The average person receives a health care service at a facility or clinic site that is registered for the 340B System and shown on the public 340B database.
So why concentrate on meaningful use than interoperability rather? Some generous explanations: As Blumenthal notes, there may be no interoperability without operability. Patient personal privacy can be another salient concern, given the increasing frequency of cyberattacks especially. Finally, the technical complexity of establishing standards is daunting. As Koppel explains, something ostensibly simple even, such as blood-pressure measurement, can get dropped in translation due to the modifiers accompanying the quantities: standing, seated, preinjection, labile, noncompliant. So imagine a common vocabulary for MRI reports or operative notes. Although market influence is indisputable, this description conflicts with the impression I acquired from Judy Faulkner, chief executive officer of EHR maker Epic Systems, who advocates for government-created criteria.